# Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis

> **NCT07197008** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Li-kun Chen** · enrollment: 50 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab

## Key facts

- **NCT ID:** NCT07197008
- **Lead sponsor:** Li-kun Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07197008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07197008, "Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07197008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*